Navigation Links
Ikaria® To Present at 2011 BIO Business Forum and International Convention
Date:6/21/2011

HAMPTON, N.J., June 21, 2011 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings, today announced that its Chairman and CEO, Daniel Tasse, will present at the 2011 Biotechnology Industry Organization (BIO) Business Forum and International Convention on Tuesday, June 28, 2011 from 2:30 to 2:45 p.m. EDT in the Georgetown Room at the Walter E. Washington Convention Center in Washington, DC.

About Ikaria, Inc.Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings.  Ikaria's therapies are designed to meet the unique and complex medical needs of these critically ill patients. The Company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. Ikaria, alone or through partners, also markets the INOMAX therapy package in Puerto Rico, Canada, Australia, Mexico and Japan. The Company is pursuing a number of new indications for INOMAX. Ikaria's late-stage pipeline also is comprised of LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1, as well as IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. The Company also has a number of investigational compounds in development. Ikaria is headquartered in Hampton, NJ, with research facilities in Seattle, WA and Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI. Please visit www.ikaria.com.Company Contact:Media Contacts:Samina Bari

Tiberend Strategic Advisors, Inc.Ikaria, Inc.

(212) 827-0020(908) 238-6372

Tamara Bright/Claire Sojdasamina.bari@ikaria.com

tbright@tiberend.comcsojda@tiberend.com
'/>"/>

SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
5. Bionovo to Present at Canaccord Adams Global Growth Conference
6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
7. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
10. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
11. Cepheid to Webcast Upcoming Financial Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... ... the CHI SCOPE Summit for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). ... to examine vital clinical research issues such as trial performance metrics, patient enrollment ...
(Date:1/18/2017)... ... January 18, 2017 , ... uBiome, the leading ... by its Science Editor, Dr. Elisabeth Bik, in the December 2016 issue of ... joined uBiome in October 2016 from her previous position at Stanford University School ...
(Date:1/18/2017)... Shareholder rights law firm Johnson & Weaver, ... members of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD ... proposed sale of the Company to Eli Lilly and ... molecules for the acute treatment of migraines. ... a definitive merger agreement with Eli Lilly. Under the ...
(Date:1/18/2017)... Jan. 18, 2017  Caris Life Sciences, a ... Foundation, the largest private funder of pancreatic cancer ... evaluating the impact of immunotherapy in the treatment ... enrollment services to identify potential trial candidates based ... treating physicians and study investigators. The Lustgarten Foundation ...
Breaking Biology Technology:
(Date:12/16/2016)...   IdentyTechSolutions America LLC , a leading ... and a cutting-edge manufacturer of software and hardware ... seamless, integrated solutions that comprise IDT biometric readers ... provide IdentyTech,s customers with combined physical identification and ... and theft. "We are proud to ...
(Date:12/15/2016)... 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... announced today that on December 13, 2016, it received ... Nasdaq Stock Market LLC which acknowledged that, as of ... common stock had been at $1.00 or greater for ... with Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
Breaking Biology News(10 mins):